- Home
- MNPR vs ICHR Comparison
MNPR vs ICHR Comparison
Compare MNPR & ICHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- ICHR
- Stock Information
- Founded
- MNPR 2014
- ICHR 1999
- Country
- MNPR United States
- ICHR United States
- Employees
- MNPR N/A
- ICHR N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- ICHR Semiconductors
- Sector
- MNPR Health Care
- ICHR Technology
- Exchange
- MNPR Nasdaq
- ICHR Nasdaq
- Market Cap
- MNPR 531.6M
- ICHR 555.0M
- IPO Year
- MNPR 2019
- ICHR 2016
- Fundamental
- Price
- MNPR $92.78
- ICHR $15.10
- Analyst Decision
- MNPR Strong Buy
- ICHR Buy
- Analyst Count
- MNPR 13
- ICHR 5
- Target Price
- MNPR $97.83
- ICHR $26.50
- AVG Volume (30 Days)
- MNPR 161.9K
- ICHR 1.0M
- Earning Date
- MNPR 11-13-2025
- ICHR 11-03-2025
- Dividend Yield
- MNPR N/A
- ICHR N/A
- EPS Growth
- MNPR N/A
- ICHR N/A
- EPS
- MNPR N/A
- ICHR N/A
- Revenue
- MNPR N/A
- ICHR $957,337,000.00
- Revenue This Year
- MNPR N/A
- ICHR $14.64
- Revenue Next Year
- MNPR N/A
- ICHR $5.82
- P/E Ratio
- MNPR N/A
- ICHR N/A
- Revenue Growth
- MNPR N/A
- ICHR 16.86
- 52 Week Low
- MNPR $18.67
- ICHR $13.12
- 52 Week High
- MNPR $105.00
- ICHR $36.48
- Technical
- Relative Strength Index (RSI)
- MNPR 64.12
- ICHR 38.61
- Support Level
- MNPR $74.58
- ICHR $14.20
- Resistance Level
- MNPR $84.06
- ICHR $15.64
- Average True Range (ATR)
- MNPR 6.71
- ICHR 1.20
- MACD
- MNPR 0.32
- ICHR -0.25
- Stochastic Oscillator
- MNPR 95.22
- ICHR 20.26
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About ICHR Ichor Holdings
Ichor Holdings Ltd is engaged in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment. The product offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The company also manufactures machined components, weldments, and proprietary products for use in fluid delivery systems. Geographically, the company operates in the United States, Singapore, Europe, and Others, of which a majority of the revenue is generated from Singapore.